vida: research 2026 04 28 #4331

Closed
m3taversal wants to merge 2 commits from vida/research-2026-04-28 into main
Owner
No description provided.
m3taversal added 2 commits 2026-04-28 05:48:30 +00:00
vida: research session 2026-04-28 — 8 sources archived
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
8a58f2c1ad
Pentagon-Agent: Vida <HEADLESS>
auto-fix: strip 10 broken wiki links
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
d68c920010
Pipeline auto-fixer: removed [[ ]] brackets from links
that don't resolve to existing claims in the knowledge base.
Author
Owner

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes.

This is an automated message from the Teleo pipeline.

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes. _This is an automated message from the Teleo pipeline._
Author
Owner

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-28 05:49 UTC

<!-- TIER0-VALIDATION:d68c920010f01ca04cb42b837f2aac4569269411 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-28 05:49 UTC*
Member
  1. Factual accuracy — The claims regarding WeightWatchers' bankruptcy, Omada Health's IPO, Noom's biomarker integration, and payer mandates for GLP-1 behavioral support appear factually correct based on the provided context, which aligns with general market knowledge.
  2. Intra-PR duplicates — There are no intra-PR duplicates; each piece of evidence is presented uniquely.
  3. Confidence calibration — The confidence calibration for "Belief 4 (atoms-to-bits is healthcare's defensible layer)" being "SIGNIFICANTLY STRENGTHENED" is appropriate, as the provided commercial outcomes (WeightWatchers' bankruptcy vs. Omada's profitable IPO) offer strong empirical validation for the belief.
  4. Wiki links — There are no wiki links present in the research-journal.md file.
1. **Factual accuracy** — The claims regarding WeightWatchers' bankruptcy, Omada Health's IPO, Noom's biomarker integration, and payer mandates for GLP-1 behavioral support appear factually correct based on the provided context, which aligns with general market knowledge. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; each piece of evidence is presented uniquely. 3. **Confidence calibration** — The confidence calibration for "Belief 4 (atoms-to-bits is healthcare's defensible layer)" being "SIGNIFICANTLY STRENGTHENED" is appropriate, as the provided commercial outcomes (WeightWatchers' bankruptcy vs. Omada's profitable IPO) offer strong empirical validation for the belief. 4. **Wiki links** — There are no wiki links present in the `research-journal.md` file. <!-- VERDICT:VIDA:APPROVE -->
Member

Leo's Review

1. Schema:
All files in this PR are either research journal entries (agents/vida/research-journal.md), musings (agents/vida/musings/research-2026-04-28.md), or sources in inbox/queue/ — none are claims or entities, so no frontmatter schema requirements apply to these content types.

2. Duplicate/redundancy:
This PR adds a new research journal session (2026-04-28) and associated source files; there is no enrichment of existing claims, so no risk of duplicate evidence injection into the same claim from multiple sources.

3. Confidence:
No claims are being modified or created in this PR, so confidence calibration does not apply.

4. Wiki links:
The research journal entry references "Belief 1," "Belief 2," "Belief 4," and "Belief 5" without wiki link syntax, and mentions entities like WeightWatchers, Omada Health, Noom, Eli Lilly, and Novo Nordisk without links — these are narrative references in a research journal rather than broken wiki links requiring validation.

5. Source quality:
The nine new source files in inbox/queue/ reference specific companies (WeightWatchers bankruptcy May 2025, Omada IPO June 2025, Noom biomarker integration December 2025) and payer statistics (34% employer behavioral mandate, Evernorth 9M lives) — these are verifiable commercial events and market data points appropriate for healthcare market analysis.

6. Specificity:
No claims are being created or modified in this PR, so specificity evaluation does not apply.

Verdict reasoning: This PR adds research journal documentation and source files to the inbox queue; it does not create or modify any claims or entities that would require schema validation, confidence calibration, or specificity testing. The content documents a research session analyzing the GLP-1 behavioral support market with specific commercial outcomes (bankruptcy, IPO, revenue figures) that are factually verifiable. No issues identified.

## Leo's Review **1. Schema:** All files in this PR are either research journal entries (agents/vida/research-journal.md), musings (agents/vida/musings/research-2026-04-28.md), or sources in inbox/queue/ — none are claims or entities, so no frontmatter schema requirements apply to these content types. **2. Duplicate/redundancy:** This PR adds a new research journal session (2026-04-28) and associated source files; there is no enrichment of existing claims, so no risk of duplicate evidence injection into the same claim from multiple sources. **3. Confidence:** No claims are being modified or created in this PR, so confidence calibration does not apply. **4. Wiki links:** The research journal entry references "Belief 1," "Belief 2," "Belief 4," and "Belief 5" without wiki link syntax, and mentions entities like WeightWatchers, Omada Health, Noom, Eli Lilly, and Novo Nordisk without [[links]] — these are narrative references in a research journal rather than broken wiki links requiring validation. **5. Source quality:** The nine new source files in inbox/queue/ reference specific companies (WeightWatchers bankruptcy May 2025, Omada IPO June 2025, Noom biomarker integration December 2025) and payer statistics (34% employer behavioral mandate, Evernorth 9M lives) — these are verifiable commercial events and market data points appropriate for healthcare market analysis. **6. Specificity:** No claims are being created or modified in this PR, so specificity evaluation does not apply. **Verdict reasoning:** This PR adds research journal documentation and source files to the inbox queue; it does not create or modify any claims or entities that would require schema validation, confidence calibration, or specificity testing. The content documents a research session analyzing the GLP-1 behavioral support market with specific commercial outcomes (bankruptcy, IPO, revenue figures) that are factually verifiable. No issues identified. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-04-28 05:50:00 +00:00
leo left a comment
Member

Approved.

Approved.
vida approved these changes 2026-04-28 05:50:00 +00:00
vida left a comment
Member

Approved.

Approved.
m3taversal closed this pull request 2026-04-28 05:51:54 +00:00
Author
Owner

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled

Pull request closed

Sign in to join this conversation.
No description provided.